{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T18:10:30Z","timestamp":1760379030810,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,2,1]],"date-time":"2012-02-01T00:00:00Z","timestamp":1328054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1016\/j.euroneuro.2011.06.005","type":"journal-article","created":{"date-parts":[[2011,8,1]],"date-time":"2011-08-01T18:52:43Z","timestamp":1312224763000},"page":"123-131","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: Long-term changes in weight and metabolic profiles"],"prefix":"10.1016","volume":"22","author":[{"given":"David E.","family":"Kemp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Onur N.","family":"Karayal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph R.","family":"Calabrese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gary S.","family":"Sachs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Pappadopulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen S.","family":"Ice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cynthia O.","family":"Siu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eduard","family":"Vieta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2011.06.005_bb0005","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.psychres.2008.10.007","article-title":"Understanding the relationship between baseline BMI and subsequent weight change in antipsychotic trials, effect modification or regression to the mean?","volume":"170","author":"Allison","year":"2009","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0165-0327(01)00377-9","article-title":"Mortality in patients with mood disorders, follow-up over 34\u201338years","volume":"68","author":"Angst","year":"2002","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1046\/j.1467-789x.2001.00027.x","article-title":"Do stress reactions cause abdominal obesity and comorbidities?","volume":"2","author":"Bjorntorp","year":"2001","journal-title":"Obes. Rev."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0020","doi-asserted-by":"crossref","first-page":"130","DOI":"10.4088\/JCP.09m05482yel","article-title":"Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder, a 6-month randomized, placebo-controlled, double-blind trial","volume":"71","author":"Bowden","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0025","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1210\/endo-127-4-1689","article-title":"Glucocorticoid receptor messenger ribonucleic acid in different regions of human adipose tissue","volume":"127","author":"Bronnegard","year":"1990","journal-title":"Endocrinology"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0030","doi-asserted-by":"crossref","first-page":"575","DOI":"10.4088\/JCP.v67n0408","article-title":"Metabolic syndrome and the risk of coronary heart disease in 367 patients treated with second-generation antipsychotic drugs","volume":"67","author":"Correll","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0255","first-page":"1","article-title":"Prevalence of metabolic syndrome among adults 20 years of age and over, by sex, age, race and ethnicity, and body mass index","volume":"13","author":"Ervin","year":"2009","journal-title":"Natl. Health Stat. Rep."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1176\/appi.ajp.160.1.112","article-title":"Obesity as a correlate of outcome in patients with bipolar I disorder","volume":"160","author":"Fagiolini","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/j.1399-5618.2005.00234.x","article-title":"Metabolic syndrome in bipolar disorder, findings from the Bipolar Disorder Center for Pennsylvania","volume":"7","author":"Fagiolini","year":"2005","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0270","unstructured":"Fauci, A.S., Braunwald, Kasper, D.L., et al., 2008. Harrison's Principles of Internal Medicine, 17th ed. McGraw Hill Medical, New York, NY."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0050","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.2337\/diacare.28.11.2745","article-title":"Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S","volume":"28","author":"Ford","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jad.2005.01.004","article-title":"Treatment guidelines for bipolar disorder, a critical review","volume":"86","author":"Fountoulakis","year":"2005","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0060","first-page":"847","article-title":"Omental and subcutaneous adipose tissues of obese subjects release interleukin-6, depot difference and regulation by glucocorticoid","volume":"83","author":"Fried","year":"1998","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0065","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.jad.2007.06.002","article-title":"The prevalence of metabolic syndrome in patients with bipolar disorder","volume":"106","author":"Garcia-Portilla","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0070","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000092219","article-title":"Atypical antipsychotic usage-related higher serum leptin levels and disabled lipid profiles in euthymic bipolar patients","volume":"53","author":"Gergerliouglu","year":"2006","journal-title":"Neuropsychobiology"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0080","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome, an American Heart Association\/ National Heart, Lung and Blood Institute scientific statement","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.euroneuro.2011.06.005_bb0280","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.4088\/JCP.v67n0707","article-title":"Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: a retrospective, population-based, case-control study","volume":"67","author":"Guo","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0085","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.4088\/JCP.v65n1214","article-title":"Weight gain during treatment for bipolar I patients with olanzapine","volume":"65","author":"Henner","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0090","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.neubiorev.2007.10.005","article-title":"Allostatic load in bipolar disorder, implications for pathophysiology and treatment","volume":"32","author":"Kapczinski","year":"2008","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0095","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1097\/01.pra.0000396061.05269.c8","article-title":"Switching from quetiapine to ziprasidone; a sixteen-week, open-label, multicenter study evaluating the effectiveness and safety of ziprasidone in outpatient subjects with schizophrenia or schizoaffective disorder","volume":"17","author":"Karayal","year":"2011","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0100","doi-asserted-by":"crossref","first-page":"626","DOI":"10.4088\/JCP.v67n0414","article-title":"A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder","volume":"67","author":"Keck","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0110","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.09m05159gre","article-title":"Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar disorder, a post-hoc analysis of a randomized, double-blind, placebo-controlled trial","author":"Kemp","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0115","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/j.1399-5618.2010.00823.x","article-title":"Medical comorbidity in bipolar disorder, relationship between illnesses of the endocrine\/metabolic system and treatment outcome","volume":"12","author":"Kemp","year":"2010","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0120","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1097\/JCP.0b013e3180a9076c","article-title":"Metabolic impact of switching antipsychotic therapy to aripiprazole after weight gain: a pilot study","volume":"27","author":"Kim","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2011.06.005_bb0260","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.jad.2007.04.006","article-title":"Weight change in the acute treatment of bipolar I disorder: a naturalistic observational study of psychiatric inpatients","volume":"105","author":"Kim","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0125","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with schizophrenia","volume":"353","author":"Lieberman","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0265","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","article-title":"Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III","volume":"80","author":"McEvoy","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0130","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.jad.2010.04.012","article-title":"Bipolar disorder and metabolic syndrome, an international perspective","volume":"126","author":"McIntyre","year":"2010","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0135","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.2337\/dc08-1720","article-title":"Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes","volume":"32","author":"Morrato","year":"2009","journal-title":"Diabetes Care"},{"issue":"Suppl. I","key":"10.1016\/j.euroneuro.2011.06.005_bb0140","first-page":"1","article-title":"Second-generation (atypical) antipsychotics and metabolic side-effects, a comprehensive literature review","volume":"19","author":"Newcomer","year":"2005","journal-title":"CNC Drugs"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0150","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1001\/archpsyc.58.9.844","article-title":"Excess mortality in bipolar and unipolar disorder in Sweden","volume":"58","author":"Osby","year":"2001","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0155","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1159\/000070584","article-title":"Serum cholesterol in treatment-resistant depression","volume":"47","author":"Papakostas","year":"2003","journal-title":"Neuropsychobioloby"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0160","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0165-1781(03)00066-0","article-title":"Serum cholesterol and serotonergic function in major depressive disorder","volume":"118","author":"Papakostas","year":"2003","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0165","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.schres.2008.09.025","article-title":"Weight effects associated with antipsychotics, a comprehensive database analysis","volume":"110","author":"Parsons","year":"2009","journal-title":"Schizophr. Res."},{"issue":"1\u20133","key":"10.1016\/j.euroneuro.2011.06.005_bb0275","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.schres.2007.10.022","article-title":"Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-na\u00efve population","volume":"99","author":"Perez-Iglesias","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0175","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.pharmthera.2009.10.010","article-title":"Metabolic side effects of antipsychotic drug treatment, pharmacological mechanisms","volume":"125","author":"Reynolds","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0180","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/YIC.0b013e3282f94905","article-title":"Assessment of clinical and metabolic status, and subject well-being in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone","volume":"23","author":"Rossi","year":"2008","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0185","doi-asserted-by":"crossref","first-page":"273","DOI":"10.4088\/JCP.v62n0410","article-title":"Long-term therapy in the treatment of bipolar I disorder, an open-label continuation phase study","volume":"62","author":"Sanger","year":"2001","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0195","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1399-5618.2007.00490.x","article-title":"Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder, a systematic review of randomized controlled trials","volume":"9","author":"Smith","year":"2007","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0200","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archpsyc.62.10.1089","article-title":"Mixed hypomania in 908 patients with bipolar disorder evaluated prospectively in the Stanley Foundation Bipolar Treatment network, a sex-specific phenomenon","volume":"62","author":"Suppes","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0205","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2008.08020189","article-title":"Maintenance treatment for patients with bipolar I disorder, results from a North American study of quetiapine in combination with lithium or divalproex (Trial 127)","volume":"166","author":"Suppes","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0210","doi-asserted-by":"crossref","first-page":"783","DOI":"10.4088\/JCP.v67n0512","article-title":"Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder, analysis of acute-phase data from a randomized controlled trial","volume":"67","author":"Thompson","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0215","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1176\/appi.ajp.163.2.247","article-title":"Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine","volume":"163","author":"Tohen","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0220","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1600-0447.2008.01204.x","article-title":"Weight gain in bipolar disorder, pharmacological treatment as a contributing factor","volume":"118","author":"Torrent","year":"2008","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0225","doi-asserted-by":"crossref","DOI":"10.1016\/j.tem.2010.01.009","article-title":"Gluttony, sloth and the metabolic syndrome, a roadmap to lipotoxicity","author":"Unger","year":"2010","journal-title":"Trends Endocrinol. Metabol"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0230","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2008.06.001","article-title":"Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (International Trial 126)","volume":"109","author":"Vieta","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0235","doi-asserted-by":"crossref","first-page":"391","DOI":"10.4088\/JCP.08m04743blu","article-title":"Obesity and onset of significant depressive symptoms, results from a prospective community-based cohort study of older men and females","volume":"71","author":"Vogelzangs","year":"2010","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0240","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/sj.npp.1301482","article-title":"Long-term changes in weight and plasma lipids during maintenance treatment with ziprasidone","volume":"33","author":"Weiden","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0245","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"WHO Expert Consultation","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2011.06.005_bb0250","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/j.1399-5618.2009.00672.x","article-title":"Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder, update 2009","volume":"11","author":"Yatham","year":"2009","journal-title":"Bipolar Disord."},{"issue":"9","key":"10.1016\/j.euroneuro.2011.06.005_bb0285","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1002\/pds.1781","article-title":"The incidence of diabetes in atypical antipsychotic users differs according to agent\u2013results from a multisite epidemiologic study","volume":"18","author":"Yood","year":"2009","journal-title":"Pharmacoepidemiol. Drug Saf."}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X11001520?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X11001520?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:50:10Z","timestamp":1760377810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X11001520"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,2]]}},"alternative-id":["S0924977X11001520"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2011.06.005","relation":{},"ISSN":["0924-977X"],"issn-type":[{"type":"print","value":"0924-977X"}],"subject":[],"published":{"date-parts":[[2012,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ziprasidone with adjunctive mood stabilizer in the maintenance treatment of bipolar I disorder: Long-term changes in weight and metabolic profiles","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2011.06.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}